trial

Efficacy of Pimozide Augmentation for Clozapine Partial Response

NCTId NCT00374244
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 28 (actual)
Sponsored by Yale University
Primary completion 2011-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
28 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2004-01
Primary completion
2011-06
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Pimozide

Sponsors

Yale UniversityLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Handan Gunduz-Bruce, MD, MBAPrincipal Investigator

Sites

2 total
New Haven, United StatesWest Haven, United States

Linked catalysts

1
Efficacy of Pimozide Augmentation for Clozapine Partial Response — primary completion2011-06

Facts & assertions

4 sourced
Enrollment
28
Phase
PHASE2
Primary Completion Date
2011-06
Status
COMPLETED
relationships
The graph out of here
drug
Pimozide
drug
lead_sponsor
Yale University
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Handan Gunduz-Bruce, MD, MBA
person